Shifting Treatment Paradigms in R/R ALL

Video content above is prompted by the following:

1. Dr. O’Dwyer to Dr. Shaughnessy: What are your impressions of the MRD outcomes with obe-cel compared with MRD outcomes reported with brexu-cel so far?
2. Resource links: Valtis YK et al. MRD negativity D28 after brexu-cel. ASH 2024 abstract, or see Appendix 5.
3. Dr. O’Dwyer to Dr. Logan [then open to panelists]: How does the FDA approval of obe-cel change your treatment landscape and decisions for R/R ALL?
4. Are there specific patients with R/R ALL for whom you would more likely consider brexu-cel vs obe-cel [eg, Philadelphia status, MRD status, high-risk features, extramedullary disease, age, performance score]?
5. Does the FDA approval without a Risk Evaluation Mitigation Strategy program influence your treatment approach?